• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Hims & Hers Health Inc.

    7/21/25 4:59:36 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001837815
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Hims & Hers Health, Inc.
    SEC File Number
    001-38986
    Address of Issuer
    2269 Chestnut Street
    Suite 523
    San Francisco
    CALIFORNIA
    94123
    Phone
    1-415-851-0195
    Name of Person for Whose Account the Securities are To Be Sold
    Melissa Baird
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A Common
    Goldman Sachs & Co. LLC
    200 West Street
    New York � NY � 10282
    333331586650.821545389907/21/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A Common05/13/2020Acquired as compensation -- Stock OptionsThe IssuerCheckbox not checked3333305/13/2020Compensation -- Cashless exercise / same-day sale

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common06/16/20255000303098
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common07/08/20255000250856.5
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common06/16/20258333498800.88
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common05/12/20258333473143.57
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common06/04/20255000289090
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common07/08/20258333411970.19
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common05/12/2025200001104788
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common05/12/20255000289444
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common06/04/20258333456620.9
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common06/04/2025200001070502
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common05/27/20258333458784.15
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common05/27/20255000277573
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common04/21/202520000511650
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common04/21/20255000131683.5
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common07/08/202520000978588
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common04/21/20258333215923.03
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common06/16/2025200001176378
    Melissa Baird
    2269 Chestnut Street
    Suite 523
    San Francisco � CA � 94123
    Class A Common05/27/2025200001076956

    144: Remarks and Signature

    Remarks
    The sales of shares set forth herein are made in connection with a selling plan dated 11/26/2024, that is intended to comply with Rule 10b5-1(c).
    Date of Notice
    07/21/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/26/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Goldman Sachs & Co. LLC on behalf of Melissa Baird

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $HIMS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    6/23/2025Buy → Hold
    Needham
    6/4/2025$61.00 → $65.00Buy
    Needham
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    1/7/2025$35.00Buy
    BTIG Research
    12/17/2024$42.00Overweight
    Morgan Stanley
    11/14/2024Buy → Underperform
    BofA Securities
    More analyst ratings

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Okupe Oluyemi exercised 11,581 shares at a strike of $5.01 and sold $556,420 worth of shares (11,581 units at $48.05), increasing direct ownership by 116% to 116,806 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/15/25 4:18:27 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Legal Officer Boughton Soleil sold $132,818 worth of shares (2,572 units at $51.64), decreasing direct ownership by 2% to 153,021 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/12/25 4:33:50 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Executive Officer Dudum Andrew sold $33,384,120 worth of shares (660,000 units at $50.58) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    8/11/25 5:07:29 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

    Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. "It's never been more clear that we are delivering exactly what millions of people have been waiti

    8/4/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Data Shows Personalized GLP-1 Plans Drive Real Weight Loss, Few Side Effects, and Strong Adherence to Care

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today released new data showing that its personalized, digital-first approach to weight loss is driving meaningful, sustainable results, laying the groundwork for lasting success. In a first-of-its-kind U.S. analysis of treatment plans, including compounded GLP-1s, customers taking a compounded GLP-1 reported losing an average of 20.9 pounds or 10.3% of initial body weight, within six months, while reporting a low rate of side effects. Just as importantly, 75% of customers remained on treatment plans in the same timeframe, a powerful signal of real-world trust and clinical success.1 This press

    7/29/25 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Second Quarter 2025 Financial Results on August 4, 2025

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's manageme

    7/14/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hims & Hers Health downgraded by Needham

    Needham downgraded Hims & Hers Health from Buy to Hold

    6/23/25 11:43:05 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Needham reiterated coverage on Hims & Hers Health with a new price target

    Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $65.00 from $61.00 previously

    6/4/25 7:59:55 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health downgraded by TD Cowen with a new price target

    TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00

    4/29/25 8:05:51 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

    5/8/25 6:50:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

    Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

    5/5/25 9:01:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Define Ventures Appoints Carolyn Magill as Venture Partner

    The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

    3/11/25 5:30:00 AM ET
    $EVH
    $HIMS
    $LVGO
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

    Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com. "It's never been more clear that we are delivering exactly what millions of people have been waiti

    8/4/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Second Quarter 2025 Financial Results on August 4, 2025

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 4, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's manageme

    7/14/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

    Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.him

    5/5/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Hims & Hers Health Inc.

    SCHEDULE 13G - Hims & Hers Health, Inc. (0001773751) (Subject)

    8/13/25 12:56:59 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Hims & Hers Health Inc.

    10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)

    8/4/25 4:18:59 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    8/4/25 4:13:03 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care